Navigation Links
HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
Date:5/23/2012

FRAMINGHAM, Mass., and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it has received an expanded European label for long-term use of the HeartWare® Ventricular Assist System in all patients at risk of death from refractory, end-stage heart failure.

"This label extension is similar to the 'Destination Therapy' indication in the United States, and having that designation now outside the U.S. provides our international customers with additional flexibility as they treat those patients who might not be eligible for heart transplantation," stated Doug Godshall, President and Chief Executive Officer.  "This new label reflects the positive long-term survival data from our international trial, as well as the longer utilization times of ventricular assist devices in Europe."

In 2009, HeartWare received CE Marking for use of the HeartWare® Ventricular Assist System in patients as a bridge to heart transplantation.  Today, more than 2,000 patients around the globe have been implanted with the HeartWare Ventricular Assist System.  Earlier this month, HeartWare reported 91 customer sites in 25 countries outside of the United States, in addition to 50 clinical sites within the U.S.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE®, HVAD®, MVAD® and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical trials, expected timing of regulatory filings and approvals, and research and development activities. Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility the FDA does not approve the marketing of the HeartWare® Ventricular Assist System in the U.S., and those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A."Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

 


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... NEW YORK , Jan. 23, 2017 MouthWatch ... Intraoral Camera was ranked as the best intraoral camera ... , taking the #2 spot overall. The #1 product was ... DentalCompare.com said the MouthWatch intraoral camera was "…incredibly popular because ... while the camera has a small sticker price, it doesn,t ...
(Date:1/23/2017)... 2017  Delcath Systems, Inc. (NASDAQ: DCTH ... of primary and metastatic liver cancers, today announced that ... and Chief Executive Officer of Delcath will be a ... Thirteenth Annual Investor Conference at the Boca Raton Resort ... , on Tuesday, January 31, 2017 at 10:30 am ...
(Date:1/23/2017)... SAN DIEGO , Jan. 23, 2017 /PRNewswire/ ... identify patients at high risk for acute kidney ... treatment recommended by globally-recognized care guidelines ... moderate to severe AKI more than 33 percent, ... weekend in the journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... Mill”: a story of love and redemption, hope and uncertainty as a girl makes ... “The Inn at the Mill” is the creation of published author, Lois Kulp, who was ... in Berks County on Crow Hill. The inn, the mill and "Post Yokel" ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
(Date:1/22/2017)... California (PRWEB) , ... January 22, 2017 , ... "Photo ... Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin - ... Generators browser to place in the FCPX timeline. Presets include scenes with ...
(Date:1/21/2017)... ... 21, 2017 , ... "ProDOF is the perfect set of tools for video editors that want ... scene," said Christina Austin - CEO of Pixel Film Studios. , Video editors using ... illusion of a DSLR racking focus from one area into the next. ProDOF comes ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
Breaking Medicine News(10 mins):